Acquisition

Frazier takes majority stake in bioengineering firm ATUM

What's the deal? Frazier Healthcare PartnersDealroom has a profile for this one. Try Dealroom → has completed a majority investment in ATUMDealroom has a profile for this one. Try Dealroom →, a Newark, California bioengineering company. The private placement was made alongside co-investors including Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, plus ATUM's existing founders and management team. Deal terms were not disclosed.

What does ATUM do? Founded in 2003 as DNA2.0Dealroom has a profile for this one. Try Dealroom →, it pairs machine learning with gene design, protein optimisation, and cell-line development through its Leap-In Transposase platform. The company says its technology has supported cell lines used in more than 50 investigational new drug submissions.

Who's backing it? Frazier, a private equity firm focused exclusively on healthcare, has raised over $11 billion since 1991 and invested in more than 200 companies. Executive in Residence Milton Boyer joins ATUM's board as executive chair; Jeremy Minshull stays on as chief executive officer.

What's the endgame? ATUM is moving beyond gene synthesis toward an integrated platform spanning biologics design, protein engineering, and cell-line development — a mix meant to shorten drug developers' path to manufacturing. "We will expand our capacity, grow our infrastructure, and innovate faster," Minshull said.

Why now? The deal follows signs of commercial traction: a December 2025 partnership with AGC BiologicsDealroom has a profile for this one. Try Dealroom → to offer ATUM's Leap-In technology through the contract manufacturer, a July 2026 cancer-therapy engagement with VERAXADealroom has a profile for this one. Try Dealroom →, and a May launch of a platform for bispecific antibodies.

Baird advised ATUM, with legal counsel from Paul HastingsDealroom has a profile for this one. Try Dealroom →. Frazier was advised by William Blair and Goodwin ProcterDealroom has a profile for this one. Try Dealroom →.

The signal: A healthcare specialist with a 35-year track record taking control of a bioengineering platform reflects investor appetite for the picks-and-shovels layer of drug development — the tools that de-risk and speed biologics to the clinic. "Rarely do we see the combination of scientific leadership and market opportunity that we do in ATUM," said Frazier principal Jeremy Janson.

Read more: markets.financialcontent.com

Image credit: Generated with Gemini

More top stories